In summary, our findings suggest that the c-myc/XTP6/NDH2/NF-κB positive feedback loop can facilitate the malignant progression of GBM (Fig. 8), offering underlying new therapeutic targets for GBM patients. Here, DLEU1 is linked to glioblastoma.